[go: up one dir, main page]

MX2016009665A - Composiciones y metodos para el tratamiento de la hemorragia cerebral. - Google Patents

Composiciones y metodos para el tratamiento de la hemorragia cerebral.

Info

Publication number
MX2016009665A
MX2016009665A MX2016009665A MX2016009665A MX2016009665A MX 2016009665 A MX2016009665 A MX 2016009665A MX 2016009665 A MX2016009665 A MX 2016009665A MX 2016009665 A MX2016009665 A MX 2016009665A MX 2016009665 A MX2016009665 A MX 2016009665A
Authority
MX
Mexico
Prior art keywords
treatment
methods
cerebral
compositions
hemorragy
Prior art date
Application number
MX2016009665A
Other languages
English (en)
Other versions
MX375355B (es
Inventor
Debra D Pittman
Fruebis Joachim
Arkin Steven
E Carr Marcus
Hett Sunita
Jasuja Reema
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2016009665A publication Critical patent/MX2016009665A/es
Publication of MX375355B publication Critical patent/MX375355B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La divulgación proporciona composiciones y métodos para el tratamiento o la prevención de la hemorragia cerebral (ICH) en un sujeto mediante la administración de una variante de FXa.
MX2016009665A 2014-01-24 2015-01-15 Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral. MX375355B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24
PCT/IB2015/050313 WO2015110939A1 (en) 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage

Publications (2)

Publication Number Publication Date
MX2016009665A true MX2016009665A (es) 2016-11-14
MX375355B MX375355B (es) 2025-03-04

Family

ID=52630418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009665A MX375355B (es) 2014-01-24 2015-01-15 Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral.

Country Status (18)

Country Link
US (2) US20160375109A1 (es)
EP (1) EP3096779B1 (es)
JP (1) JP6624787B2 (es)
KR (3) KR20180014221A (es)
CN (2) CN105934250A (es)
AU (1) AU2015208819B2 (es)
BR (1) BR112016014617A2 (es)
CA (1) CA2937418A1 (es)
DK (1) DK3096779T3 (es)
ES (1) ES2772802T3 (es)
HU (1) HUE047588T4 (es)
IL (1) IL246637A0 (es)
MX (1) MX375355B (es)
PL (1) PL3096779T3 (es)
PT (1) PT3096779T (es)
RU (1) RU2016126423A (es)
SI (1) SI3096779T1 (es)
WO (1) WO2015110939A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014210830A1 (en) * 2013-01-31 2015-07-16 Pfizer Inc. Compositions and methods for counteracting Factor Xa inhibition
MX373466B (es) 2013-09-24 2020-05-25 Pfizer Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005016406D1 (de) * 2004-06-21 2009-10-15 Novo Nordisk Healthcare Ag Faktor viia oder faktor viia äquivaltenen zur prävention oder abschwächung des wachstums von hämorrhagien und/oder der ödemerzeugung nach intrazerebraler hämorrhagie (ich)
MX2008006313A (es) 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
US8354377B2 (en) * 2008-01-18 2013-01-15 Novo Nordisk Health Care Ag Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ICH) in a selected subpopulation of ICH patients
WO2011008885A1 (en) * 2009-07-15 2011-01-20 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
CN102470182A (zh) * 2009-08-20 2012-05-23 德国杰特贝林生物制品有限公司 用于在出血性紊乱的治疗和预防性处理中进行非静脉内施用的白蛋白融合凝血因子
WO2013049804A1 (en) * 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
CN104755492A (zh) * 2012-07-25 2015-07-01 催化剂生物科学公司 修饰的因子x多肽及其应用
AU2014210830A1 (en) * 2013-01-31 2015-07-16 Pfizer Inc. Compositions and methods for counteracting Factor Xa inhibition

Also Published As

Publication number Publication date
PT3096779T (pt) 2020-02-21
RU2016126423A3 (es) 2018-03-01
HUE047588T4 (hu) 2020-06-29
JP2015147764A (ja) 2015-08-20
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
CA2937418A1 (en) 2015-07-30
AU2015208819B2 (en) 2020-01-23
RU2016126423A (ru) 2018-03-01
EP3096779A1 (en) 2016-11-30
MX375355B (es) 2025-03-04
US20190231856A1 (en) 2019-08-01
JP6624787B2 (ja) 2019-12-25
AU2015208819A1 (en) 2016-06-30
HUE047588T2 (hu) 2020-04-28
CN105934250A (zh) 2016-09-07
KR20160093731A (ko) 2016-08-08
ES2772802T3 (es) 2020-07-08
WO2015110939A1 (en) 2015-07-30
US20160375109A1 (en) 2016-12-29
KR20180014221A (ko) 2018-02-07
SI3096779T1 (sl) 2020-03-31
BR112016014617A2 (pt) 2017-09-19
CN112156176A (zh) 2021-01-01
EP3096779B1 (en) 2019-12-18
DK3096779T3 (da) 2020-02-24
IL246637A0 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
IL280785A (en) Human plasma kallikrein inhibitors
IL253123A0 (en) Preparations for administration through the skin and their uses
ES2769863T8 (es) 7-hidroxi-cannabidivarín (7-OH-CBDV) para usar en el tratamiento de la epilepsia
EP3110820A4 (en) Tyk2 inhibitors and uses thereof
LT3137169T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
BR112016030697A2 (pt) inibidores da desmetilase-1 específica da lisina
HUE058852T2 (hu) Lizinspecifikus demetiláz-1 inhibitorai
IL254779A0 (en) Methods of administering glutaminase inhibitors
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
GB201615282D0 (en) Tankyrase inhibitors
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
PL3189116T3 (pl) Szczelinowanie slick-water z użyciem uwalnianego w czasie środka kompleksującego metal
IL247116A0 (en) Compositions and methods for treating and preventing macular degeneration
EP3233061A4 (en) Method and compositions for dissolving or solubilizing therapeutic agents
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
DK3240821T3 (da) Lavdosis gashydrathæmmersammensætning og tilhørende fremgangsmåde
PL3226888T3 (pl) Podawanie selektywnego transsygnałowego inhibitora IL-6
HUE052990T2 (hu) Új kallikrein 7 gátlók
SI3197556T1 (sl) Sestavek za preprečevanje in/ali zdravljenje alergijskih simptomov
MX2016009665A (es) Composiciones y metodos para el tratamiento de la hemorragia cerebral.
IL247616B (en) Centrally acting acetylcholinesterase inhibitors for the prevention/or treatment of chemically induced neurodegenerative diseases and their symptoms, and corresponding compositions, uses, methods and kit
DK3157510T3 (da) Antimikrobielle sammensætninger med brusemidler
FR3022461B1 (fr) Methodes therapeutiques et compositions
BR112018007290A2 (pt) minha patente 1
TH1601002061A (th) สารผสมที่มีตัวยับยั้งฮิตโตนดีอะซิติเลส และยาปรับภูมิคุ้มกัน

Legal Events

Date Code Title Description
FG Grant or registration